EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)

A Phase I, Open-Label, Sequential, Single-Dose Clinical Trial to Evaluate the Pharmacokinetic, Pharmacodynamic, and Safety of IVL3001, a Finasteride-Based Novel Long-Acting Injection for Androgenetic Alopecia

Heesun Kim, Choongho Ryu, Mase Lee, Kyeong-Ryoon Lee, Juhee Kim iD

Advances in Therapy · 2024-07 · 41 (7) · 2936-2952

DOI: 10.1007/s12325-024-02890-1 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Advances in Therapy, online erschienen am 04.06.2024. Verfasst von Heesun Kim und 4 weiteren Autor:innen. Beteiligte Einrichtung: Inventage Lab, 9F Uspace2B, 670, Daewangpangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 13494, Republic of Korea. Hauptthemen laut MEDLINE: Finasteride, Alopecia, 5-alpha Reductase Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: inventageLab.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Hair loss is driven by multiple factors, including genetics. Androgenetic alopecia (AGA) is a condition in which treatments necessitate prolonged compliance with prescribed medications. We have developed IVL3001, a long-acting injectable (LAI) formulation of finasteride encapsulated within poly lactic-co-glycolic acid microspheres, to enhance the efficacy of the finasteride and to achieve consistent positive outcomes in adults. An open-label, sequential, single-dose phase I clinical trial was designed to evaluate the safety, pharmacokinetic (PK), and pharmacodynamic (PD) of IVL3001. METHODS: A total of 40 non-smoking, healthy adult males were divided into three cohorts where the IVL3001 group received a single subcutaneous injection of 12-36 mg IVL3001 and 1 mg finasteride (Propecia®) once daily for 28 days. The plasma concentrations of finasteride, dihydrotestosterone (DHT), and testosterone were measured using liquid chromatography-tandem mass spectrometry. The tolerability of the injections was assessed, and compartment models were developed to predict the effective dose and assess PK/PD profiles. RESULTS: IVL3001 and finasteride 1 mg tablets were well tolerated. IVL3001 showed consistent plasma concentrations without bursts or fluctuations. Consistent with its mechanism of action, IVL3001 reduced DHT levels. Simulation data showed that the administration of 12-36 mg of IVL3001 every 4 weeks achieved plasma concentrations similar to finasteride, with comparable DHT reduction. CONCLUSION: The present study represents the first clinical trial to evaluate the safety, pharmacokinetic (PK), pharmacodynamic (PD), and tolerability of finasteride long-acting injectables (LAI) in adults. The rapid onset of action sustained effective drug concentration and the prolonged half-life of IVL3001 suggest that it offers multiple benefits over conventional oral formulations in terms of therapeutic response and compliance. TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT04945226.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FinasterideAlopecia5-alpha Reductase InhibitorsHumansMaleAdultDihydrotestosteroneMiddle AgedDelayed-Action PreparationsTestosteroneInjections, SubcutaneousYoung AdultMicrospheres

Stichwörter der Autor:innen

AGADihydrotestosteroneFinasterideHair lossIVL3001Long-acting injectables

Substanzen

Finasteride5-alpha Reductase InhibitorsDihydrotestosteroneDelayed-Action PreparationsTestosterone

Autor:innen und Institutionen

  • Inventage Lab, 9F Uspace2B, 670, Daewangpangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 13494, Republic of Korea.
  • Department of Clinical Research Design & Evaluation, SAIHST, Sungkyunkwan University, Seoul, 06355, Republic of Korea.
  • Laboratory Animal Resource Center, Korea Research Institute of Bioscience and Biotechnology, Cheongju, 28116, Republic of Korea.
  • Inventage Lab, 9F Uspace2B, 670, Daewangpangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 13494, Republic of Korea. jade@inventagelab.com.

ORCID-Profile: Juhee Kim

Förderung

  • inventageLab

Zitieren

APA

Kim, H., Ryu, C., Lee, M., Lee, K. R., & Kim, J. (2024). A Phase I, Open-Label, Sequential, Single-Dose Clinical Trial to Evaluate the Pharmacokinetic, Pharmacodynamic, and Safety of IVL3001, a Finasteride-Based Novel Long-Acting Injection for Androgenetic Alopecia. Advances in Therapy, 41(7), 2936-2952. https://doi.org/10.1007/s12325-024-02890-1

Vancouver

Kim H, Ryu C, Lee M, Lee KR, Kim J. A Phase I, Open-Label, Sequential, Single-Dose Clinical Trial to Evaluate the Pharmacokinetic, Pharmacodynamic, and Safety of IVL3001, a Finasteride-Based Novel Long-Acting Injection for Androgenetic Alopecia. Advances in Therapy. 2024;41(7):2936-2952. doi:10.1007/s12325-024-02890-1

BibTeX
@article{Kim2024,
  author = {Kim, Heesun and Ryu, Choongho and Lee, Mase and Lee, Kyeong-Ryoon and Kim, Juhee},
  title = {A Phase I, Open-Label, Sequential, Single-Dose Clinical Trial to Evaluate the Pharmacokinetic, Pharmacodynamic, and Safety of IVL3001, a Finasteride-Based Novel Long-Acting Injection for Androgenetic Alopecia},
  journal = {Advances in Therapy},
  year = {2024},
  volume = {41},
  number = {7},
  pages = {2936--2952},
  doi = {10.1007/s12325-024-02890-1}
}
Kostenlos starten →